Učitavanje...
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
The management of chronic myeloid leukemia (CML) has been revolutionized by the discovery of tyrosine kinase inhibitors (TKIs) against BCR-ABL1 oncogenic fusion protein. Imatinib, the first BCR-ABL1 TKI, was introduced into clinical practice in the early 2000s. In the following years, the so-called...
Spremljeno u:
| Izdano u: | Oncol Ther |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Healthcare
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7360015/ https://ncbi.nlm.nih.gov/pubmed/32699984 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-019-00098-w |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|